Rupatadine

Rupatadine is a second-generation non-selective histamine receptor antagonist used primarily in the treatment of allergic rhinitis and chronic urticaria. It works by competing with histamine, a chemical released during an allergic reaction, at histamine receptors on the cell surface, thereby blocking its action and reducing allergic symptoms.

Rupatadine was first approved for use in the European Union in 2007 under the brand name Rupafin, and has since been approved in other countries including Japan, Mexico, and several countries in South America. It is available in oral tablet form and is taken once daily.

In clinical trials, rupatadine has been shown to be effective in the treatment of allergic rhinitis, reducing symptoms such as runny nose, sneezing, itching, and congestion. It has also been found to be effective in the treatment of chronic urticaria, a condition characterized by recurrent hives that are not caused by an allergic reaction. Side effects of rupatadine are generally mild and include drowsiness, headache, and dry mouth.

Rupatadine belongs to a class of medications known as second-generation antihistamines, which are known for having a lower risk of sedation compared to first-generation antihistamines. It is also less likely to interact with other medications compared to other antihistamines.

Rupatadine is indicated for use in adults and children aged 12 and older for the treatment of allergic rhinitis and chronic urticaria. However, it should not be used by individuals with certain medical conditions, such as glaucoma, and with certain medications, such as sedatives and tranquilizers.